The estimated Net Worth of Jeffry R. Keyes is at least $6.29 mil dollars as of 5 September 2017. Jeffry Keyes owns over 1,450 units of Cns Pharmaceuticals Inc stock worth over $6,291 and over the last 12 years Jeffry sold CNSP stock worth over $0.
Sign up
Jeffry Keyes CNSP stock SEC Form 4 insiders trading
Jeffry has made over 9 trades of the Cns Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Jeffry bought 1,450 units of CNSP stock worth $5,032 on 5 September 2017.
The largest trade Jeffry's ever made was exercising 10,000 units of Cns Pharmaceuticals Inc stock on 5 May 2015 worth over $19,800. On average, Jeffry trades about 1,531 units every 64 days since 2012. As of 5 September 2017 Jeffry still owns at least 39,318 units of Cns Pharmaceuticals Inc stock.
You can see the complete history of Jeffry Keyes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jeffry Keyes's mailing address?
Jeffry's mailing address filed with the SEC is C/O CNS PHARMACEUTICALS, INC., 100 WEST LOOP SOUTH, SUITE 900, HOUSTON, TX, 77027.
Insiders trading at Cns Pharmaceuticals Inc
Over the last 5 years, insiders at Cns Pharmaceuticals Inc have traded over $132,960 worth of Cns Pharmaceuticals Inc stock and bought 509,021 units worth $458,622 . The most active insiders traders include Christopher Downs, John M Climaco y Waldemar Priebe. On average, Cns Pharmaceuticals Inc executives and independent directors trade stock every 79 days with the average trade being worth of $6,051. The most recent stock trade was executed by Jerzy Gumulka on 1 February 2024, trading 33,333 units of CNSP stock currently worth $10,000.
What does Cns Pharmaceuticals Inc do?
cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.
What does Cns Pharmaceuticals Inc's logo look like?
Complete history of Jeffry Keyes stock trades at Digirad Corp y Cns Pharmaceuticals Inc
Cns Pharmaceuticals Inc executives and stock owners
Cns Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
John Michael Climaco Esq., J.D.,
Chairman, CEO & Pres -
Christopher S. Downs CPA, CTP, FP&A,
Chief Financial Officer -
Dr. Sandra L. Silberman M.D., Ph.D.,
Chief Medical Officer -
Dr. Donald H. Picker Ph.D.,
Chief Science Officer -
Dr. Waldemar Priebe Ph.D.,
Founder & Chairman of the Scientific Advisory Board -
Amy Mahery,
Director -
Biosciences, Inc. Cortice,
-
Christopher Downs,
Chief Financial Officer -
Jerzy Gumulka,
Director -
Carl Anthony Evans,
Director -
Jeffry R. Keyes,
Director -
John M Climaco,
Chief Executive Officer -
Waldemar Priebe,
-
Faith L. Charles,
Director -
Bettina M. Cockroft,
Director